When managing long-term PPI therapy, what monitoring strategy is recommended to minimize risks?

• A. Continue indefinitely at the same dose without reassessment.
• B. Reassess periodically and consider stepping down to the lowest effective dose.
• C. Only reassess if the patient develops symptoms; otherwise no changes.
• D. Switch to an entirely different class after six weeks.

Answer: (B)

Periodic reassessment of ongoing PPI therapy with a plan to taper to the lowest effective dose is the recommended approach to minimize long-term risks. Prolonged PPI use carries potential adverse effects—nutrient malabsorption (such as B12, iron, and calcium), higher fracture risk, kidney issues, and certain infections—whose likelihood increases with time and dose. By regularly evaluating whether the medication is still needed and attempting to reduce the dose while keeping symptoms controlled, you maintain therapeutic benefit while reducing exposure to the drug. If symptoms recur during stepping down, you can adjust the dose back up briefly, but the goal is to=find the minimum dose that maintains relief. When a patient cannot taper, reassess the indication, consider intermittent or on-demand strategies, lifestyle modifications, or alternative therapies to continue safe symptom control.